You need to profile your AAV vector to ensure you are developing an effective gene therapy delivery system. In this mini-guide, learn about 4 technologies that give you a full stability profile of your gene therapy vector. From serotype assessment, to monitoring aggregate formation, to checking vector purity, to evaluating capsid assembly and genetic fill — these 4 technologies will help you identify the best formulation and multi-parameter quality control of AAVs, so you build more effective gene therapy vectors.
Want to see more
gene therapy content?
See more related content
![5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fnanotempertech.com%2Fwp-content%2Fuploads%2F2022%2F08%2Fdominoes-Featured-Image.png&size=1&version=1720526038&sig=283de433f2bdf2bca160319b4ef1ec42&default=hubs%2Ftilebg-blogs.jpg)
As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...
![Serotyping: why, when, and how to assess your AAV therapeutic to get it approved](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzYyYmY4NGFmNzVkODYucG5nJnZlcnNpb249MDAwMCZzaWc9MzZjMDM0Mzg1OWQ4YjQyNjEwZmU4MzRjOTNlNjM3ZjQ%25253D&size=1&version=1665679078&sig=cb5c3a0c54a9c4fbb0552ee8176d83ff&default=hubs%2Ftilebg-videos.jpg)
When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved. As part
![8 Gene Therapy conferences you should attend in 2022](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fnanotempertech.com%2Fwp-content%2Fuploads%2F2022%2F05%2Funique-minds-Featured-Image.png&size=1&version=1720526038&sig=d791187aef881c93365a86f76ca60566&default=hubs%2Ftilebg-blogs.jpg)
Here are 8 gene therapy conferences in 2022 that will help you stay up to date. You can choose larger conferences with a broad variety of topics and many attendees, or smaller ones dedicated to...
![NanoTemper Technologies arms gene therapy scientists with Static Light Scattering to sharpen their tool kit for development of AAVs](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fnanotempertech.com%2Fwp-content%2Fuploads%2F2020%2F09%2Fpr-press-ft.png&size=1&version=1720526038&sig=16170ce1a3af237af8155bca5bb29887&default=hubs%2Ftilebg-blogs.jpg)
NanoTemper Technologies today announced the addition of Static Light Scattering (SLS) to their wildly successful Prometheus Panta, turning their instrument best known for being the new gold...
![Overcome bottlenecks in viral vector manufacturing](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzYxOTIzYzkzZTFjYmIuanBnJnZlcnNpb249MDAwMCZzaWc9NTEwYWJhYjViYmRmNjVhOWUwYjk3NzY5Y2I0YTRhZTI%25253D&size=1&version=1715958537&sig=7333fc9d8a85b8437071c031e939a909&default=hubs%2Ftilebg-videos.jpg)
The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developi
![How to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzYxODQ2ZDc0MTVkMzMucG5nJnZlcnNpb249MDAwMCZzaWc9MjIyNTBlMzAzNGE5MTQwNTU0Y2ViY2YzNjRjNDZmYTA%25253D&size=1&version=1665679078&sig=444ae4a48eb83ae950bb5d8d84ef295c&default=hubs%2Ftilebg-videos.jpg)
Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres
![The importance of molecular interactions and stability in Gene Therapy](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzVlZjM5YWUyYzQ0OTgucG5nJnZlcnNpb249MDAwMCZzaWc9ZWJlZmVlNDE0NDIzMzBmZDQ3NGNlOWU3YWNkNDVkMWM%25253D&size=1&version=1665679078&sig=e48d899330093a878a4cafd5366a766c&default=hubs%2Ftilebg-videos.jpg)
New advances in gene therapy have triggered a resurgence of interest in the field. Though gene therapy offers exciting potential for the treatment of both monogenic disorders as well as more genetical
![Solutions for gene therapy using a deeper analytical characterization of AAV vector development](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzVlOTYyMTE1YmVhYzAucG5nJnZlcnNpb249MDAwMCZzaWc9NWMyZGZhMmYzODY2Y2Y5MmVkZmZkYzc3NjJmZDg3NjM%25253D&size=1&version=1665679078&sig=4ce0d861c276607918c92da6a4cc26f5&default=hubs%2Ftilebg-videos.jpg)
Gene therapy—a type of DNA-based medicine that utilizes a virus to insert a healthy gene into cells to replace a mutated, disease-causing variant has emerged as one of the most promising medical treat
![Methods Matter: Standard production platforms for recombinant AAV produce chemically and functionally distinct vectors](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzYwZDYyYWRiZTY0MWUucG5nJnZlcnNpb249MDAwMCZzaWc9NGI5MzMxOGFhMTE3ZDUzN2QzNTI2ZGRjMzE1YzFjMmY%25253D&size=1&version=1665679078&sig=2ddc3a8c5fa330c2bd15ddee86e86cef&default=hubs%2Ftilebg-blogs.jpg)
![Quantitation of trace levels of DNA released from disrupted Adeno-associated virus gene therapy vectors](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzYwZDYyOGJhMDhkMTAucG5nJnZlcnNpb249MDAwMCZzaWc9OTkxNjEzOGZkZDg2NWEzMmM2YWQ4YWRjYTNlNTE1NWQ%25253D&size=1&version=1665679078&sig=84d7a7a462da8f1f59f2425050b247c2&default=hubs%2Ftilebg-blogs.jpg)
![Practical strategies for overcoming challenges in the development of AAV vectors for gene therapy](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzYwM2Q0YjdlMzZiODcucG5nJnZlcnNpb249MDAwMCZzaWc9OGUyMGNkODhmNmZlODA4Y2ExZTNmODZiZThjYmRjMmE%25253D&size=1&version=1665679078&sig=e4c26f1cf5018969f1dd8d508045ed1c&default=hubs%2Ftilebg-videos.jpg)
Gene therapy promises to treat and potentially cure a disease by correcting its underlying genetic cause. While gene therapies that utilize AAV vectors have shown encouraging results —including a few
![Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzVlZTkyNWJmMmFkYzUucG5nJnZlcnNpb249MDAwMCZzaWc9MzU1ZjE5MWNjNjkyNzdjZDE4NWM2YmQyZWQ5OTBlNjk%25253D&size=1&version=1665679078&sig=e5dd9ee2944ef361769d591420b929e3&default=hubs%2Ftilebg-blogs.jpg)
![Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzVlZTkyNDY2YTk3YWYucG5nJnZlcnNpb249MDAwMCZzaWc9Zjc5OGQzOGVjNDkzZmMxZGUxMjlhZTA4N2Y0NzJhODU%25253D&size=1&version=1665679078&sig=bc6dfb58588daf05e3daa87655f54a66&default=hubs%2Ftilebg-blogs.jpg)
![Intrinsic differential scanning fluorimetry for fast and easy identification of Adeno-Associated Virus serotypes](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzVlZTkzNTc0MmQ3YTgucG5nJnZlcnNpb249MDAwMCZzaWc9ZDFhNDZjMDY3YmRhOWY1NGMzMTkyNGQxZTc1YTA1ZmI%25253D&size=1&version=1665679078&sig=bb3248825b0bfc4684d66f29f820cac1&default=hubs%2Ftilebg-blogs.jpg)
![Humanized Selective CD19CAR-T Cells Treatment Shows Efficacy in B-ALL Patients Who Relapsed after Receiving Murine-Based CD19CAR-T Therapies](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzVlZTkyMDU1MjUyNjAucG5nJnZlcnNpb249MDAwMCZzaWc9ZjM0YzMzZDVhNTU4MDk4MWE2YTI0ZjM0MzZkM2ZiZTg%25253D&size=1&version=1665679078&sig=361d7c45080bd890699058cdaa15fb75&default=hubs%2Ftilebg-blogs.jpg)
![Spatial screening of hemagglutinin on Influenza A Virus particles: Sialyl-LacNAc displays on DNA and PEG scaffolds reveal requirements](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTg2NTQ5JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzVlZTkyMzU0ZTUxOTcucG5nJnZlcnNpb249MDAwMCZzaWc9NTUxMDI5MDE3OWUzYzkwNjJhMzM2ZmZlYmM1M2UyY2U%25253D&size=1&version=1665679078&sig=a8e7b3682162d9505e99fda10e417604&default=hubs%2Ftilebg-blogs.jpg)